Thursday, March 28, 2024
Home Tags Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

Tag: Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

Sorrento Therapeutics, Inc.

Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for...

0
- Novel Anti-CD38 CAR-T and Anti-CD123 CAR-T Programs Utilizing Sorrento's Fully Human Antibodies Demonstrated Strong Anti-Tumor Activity in Preclinical Models of Multiple Myeloma and Acute Myeloid Leukemia, respectively - IND Filings Are Planned for H1...

Adblocker detected! Please consider reading this notice.

We've detected that you are using AdBlock Plus or some other adblocking software which is preventing the page from fully loading.

We don't have any banner, Flash, animation, obnoxious sound, or popup ad. We do not implement these annoying types of ads!

We need money to operate the site, and almost all of it comes from our online advertising.

Please add https://www.ibgnews.com to your ad blocking whitelist or disable your adblocking software.

×
error: Sorry Content is protected !!
Verified by MonsterInsights